A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
about
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
description
scientific article published on 24 June 2019
@en
name
A phase I dose-reduction study ...... ve stage IV non-squamous NSCLC
@en
type
label
A phase I dose-reduction study ...... ve stage IV non-squamous NSCLC
@en
prefLabel
A phase I dose-reduction study ...... ve stage IV non-squamous NSCLC
@en
P2093
P1476
A phase I dose-reduction study ...... ve stage IV non-squamous NSCLC
@en
P2093
Chengzhi Cai
Meijuan Huang
Yongmei Liu
Yongsheng Wang
Youling Gong
Zhenyu Ding
P304
P356
10.1007/S10637-019-00811-6
P577
2019-06-24T00:00:00Z